Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy

Bonaldo, Paolo; Braghetta, Paola; Zanetti, Miriam; Piccolo, Stefano; Volpin, Dino; Bressan, Giorgio M.

doi:10.1093/hmg/7.13.2135

Cited by 270 publications

(254 citation statements)

References 24 publications

Supporting

Mentioning

239

Contrasting

Unclassified

Order By: Relevance

“…Collagen VI-deficient mice showed myopathic lesions similar to those described in human Bethlem myopathy [15]. In order to dissect the pathogenetical mechanisms leading to myopathic defects, detailed structural and functional investigations were performed on muscles from collagen VIdeficient and control mice.…”

Section: Syndrome Of Myosclerosismentioning

confidence: 91%

Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, 23–24 November 2001, Naarden, The Netherlands

Pepe

Bertini

Bonaldo

et al. 2002

Neuromuscular Disorders

View full text Add to dashboard Cite

Section: Syndrome Of Myosclerosismentioning

confidence: 91%

Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, 23–24 November 2001, Naarden, The Netherlands

Pepe

Bertini

Bonaldo

et al. 2002

Neuromuscular Disorders

View full text Add to dashboard Cite

“…Collagen is crucial to the bone matrix, but the most common bone collagen is Collagen type 1, with far less being known about COL6A1, though its mutations are linked to muscularskeletal defects such as Bethlam myopathy and Ulrich Congentical Muscular Distrophy [51][52][53][54]. Interestingly, a recent secretome analysis identified COL6A1 as a strongly upregulated protein in the conditioned media of metastatic, as compared to non-metastatic lung cancer cell lines [55].…”

Section: Mario Andres Blanco Et Al 1349mentioning

confidence: 99%

Global secretome analysis identifies novel mediators of bone metastasis

et al. 2012

View full text Add to dashboard Cite

Bone is the one of the most common sites of distant metastasis of solid tumors. Secreted proteins are known to influence pathological interactions between metastatic cancer cells and the bone stroma. To comprehensively profile secreted proteins associated with bone metastasis, we used quantitative and non-quantitative mass spectrometry to globally analyze the secretomes of nine cell lines of varying bone metastatic ability from multiple species and cancer types. By comparing the secretomes of parental cells and their bone metastatic derivatives, we identified the secreted proteins that were uniquely associated with bone metastasis in these cell lines. We then incorporated bioinformatic analyses of large clinical metastasis datasets to obtain a list of candidate novel bone metastasis proteins of several functional classes that were strongly associated with both clinical and experimental bone metastasis. Functional validation of selected proteins indicated that in vivo bone metastasis can be promoted by high expression of (1) the salivary cystatins CST1, CST2, and CST4; (2) the plasminogen activators PLAT and PLAU; or (3) the collagen functionality proteins PLOD2 and COL6A1. Overall, our study has uncovered several new secreted mediators of bone metastasis and therefore demonstrated that secretome analysis is a powerful method for identification of novel biomarkers and candidate therapeutic targets.

show abstract

“…An animal model of human Bethlem myopathy has already been described and the details about the composition and the role of collagen VI have been widely discussed 117,142 .…”

Section: Therapeutic Perspectivesmentioning

confidence: 99%

Congenital muscular dystrophy. Part II: a review of pathogenesis and therapeutic perspectives

Reed

2009

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-The congenital muscular dystrophies (CMDs) are a group of genetically and clinically heterogeneous hereditary myopathies with preferentially autosomal recessive inheritance, that are characterized by congenital hypotonia, delayed motor development and early onset of progressive muscle weakness associated with dystrophic pattern on muscle biopsy. The clinical course is broadly variable and can comprise the involvement of the brain and eyes. From 1994, a great development in the knowledge of the molecular basis has occurred and the classification of CMDs has to be continuously up dated. In the last number of this journal, we presented the main clinical and diagnostic data concerning the different subtypes of CMD. In this second part of the review, we analyse the main reports from the literature concerning the pathogenesis and the therapeutic perspectives of the most common subtypes of CMD: MDC1A with merosin deficiency, collagen VI related CMDs (Ullrich and Bethlem), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscleeye-brain disease, Walker Warburg syndrome, MDC1C, MDC1D), and rigid spine syndrome, another much rare subtype of CMDs not related with the dystrophin/glycoproteins/extracellular matrix complex.Key WorDs: congenital muscular dystrophy, MDC1A, collagen VI related disorders, glycosylation of alphadystroglycan, Fukuyama DMC, muscle-eye-brain (MeB) disease, Walker-Warburg syndrome, rigid spine syndrome. distrofia muscular congênita. parte ii: revisão da patogênese e perspectivas terapêuticas resumo -As distrofias musculares congênitas (DMCs) são miopatias hereditárias geralmente, porém não exclusivamente, de herança autossômica recessiva, que apresentam grande heterogeneidade genética e clínica. são caracterizadas por hipotonia muscular congênita, atraso do desenvolvimento motor e fraqueza muscular de início precoce associada a padrão distrófico na biópsia muscular. o quadro clínico, de gravidade variável, pode também incluir anormalidades oculares e do sistema nervoso central. A partir de 1994, os conhecimentos sobre genética e biologia molecular das DMCs progrediram rapidamente, sendo a classificação continuamente atualizada. os aspectos clínicos e diagnósticos dos principais subtipos de DMC foram apresentados no número anterior deste periódico, como primeira parte desta revisão. Nesta segunda parte apresentaremos os principais mecanismos patogênicos e as perspectivas terapêuticas dos subtipos mais comuns de DMC: DMC tipo 1A com deficiência de merosina, DMCs relacionadas com alterações do colágeno VI (Ullrich e Bethlem), e DMCs com anormalidades de glicosilação da alfa-distroglicana (DMC Fukuyama, DMC "Muscle-eye-brain" ou MeB, síndrome de Walker Warburg, DMC tipo 1C, DMC tipo 1D). A DMC com espinha rígida, mais rara e não relacionada com alterações do complexo distrofina-glicoproteínas associadas-matriz extracelular também será abordada quanto aos mesmos aspectos patogênicos e terapêuticos.PAlAVrAs-ChAVes: distrofia muscular congênita, merosina, colágeno VI, glicosila...

show abstract

Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy

Cited by 270 publications

References 24 publications

Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, 23–24 November 2001, Naarden, The Netherlands

Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, 23–24 November 2001, Naarden, The Netherlands

Global secretome analysis identifies novel mediators of bone metastasis

Congenital muscular dystrophy. Part II: a review of pathogenesis and therapeutic perspectives

Contact Info

Product

Resources

About